Cipher Pharmaceuticals

232 articles with Cipher Pharmaceuticals

• Cipher Pharmaceuticals Schedules Q2 2022 Earnings Release and Conference Call

  8/5/2022

  Cipher Pharmaceuticals Inc. today announced that it will release its Q2 2022 financial results on Thursday, August 11, 2022 after market close.

• Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders and Thanks Director Dr. John Mull

  6/22/2022

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 13, 2022 were approved by the requisite majority of votes cast at the meeting.

• Cipher Pharmaceuticals Reports Strong First Quarter 2022 Financial Results

  5/12/2022

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31, 2022.

• Cipher Pharmaceuticals Announces Partner, Moberg Pharma's Regulatory Submission to FDA for North American Phase 3 Study

  3/22/2022

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has submitted a regulatory filing for the next clinical Phase 3 study for MOB-015 (nail fungus treatment) to the U.S. Food and Drug Administration ("FDA").

• Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

  3/17/2022

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the year ended December 31, 2021.

• Cipher Pharmaceuticals Schedules Q4 2021 Earnings Release and Conference Call

  3/11/2022

  Cipher Pharmaceuticals Inc. announced that it will release its financial and operating results for the three and twelve months ended December 31, 2021 after market close on March 17, 2022.

• Cipher Pharmaceuticals Announces Extension of Distribution and Supply Agreement with Sun Pharmaceutical Industries Inc.

  3/10/2022

  Cipher Pharmaceuticals Inc. announced that it has entered into a second amended and restated distribution and supply agreement with Sun Pharmaceutical Industries, Inc., a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, India.

• Cipher Announces Third Quarter and Year-to-Date 2021 Financial Results

  11/11/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and nine months ended September 30, 2021.

• Cipher Pharmaceuticals Schedules Q3 2021 Earnings Release and Conference Call

  11/3/2021

  Cipher Pharmaceuticals Inc. today announced that it will release its Q3 2021 financial results on Thursday, November 11, 2021

• Cipher Pharmaceuticals Announces Renewal of Normal Course Issuer Bid

  9/8/2021

   Cipher Pharmaceuticals Inc. announced today that it has filed, and the Toronto Stock Exchange has accepted, notice of Cipher's intention to renew its normal course issuer bid for its common shares

• Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica

  8/12/2021

  Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and six-months ended June 30, 2021.

• Cipher Pharmaceuticals Schedules Q2 2021 Earnings Release and Conference Call

  8/9/2021

  Cipher Pharmaceuticals Inc. today announced it will release its Q2 2021 financial results on Thursday, August 12 , 2021.  The company will hold a conference call on Friday, August 13, 2021 to discuss the results.  

• Cipher Pharmaceuticals Reports Voting Results From Annual Meeting of Shareholders

  6/23/2021

   Cipher Pharmaceuticals Inc. today announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. 

• Cipher Pharmaceuticals Reports First Quarter 2021 Financial Results

  5/13/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31, 2021.

• Cipher Pharmaceuticals Schedules Q1 2021 Earnings Release and Conference Call

  5/5/2021

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021.  The company will hold a conference call on Friday, May 14, 2021 to discuss the results.

• Cipher Pharmaceuticals Announces Automatic Repurchase Plan Pursuant to its Normal Course Issuer Bid

  3/25/2021

  Cipher Pharmaceuticals Inc. announced that it has received approval from the Toronto Stock Exchange to amend its normal course issuer bid in order to enter into an automatic repurchase plan with its designated broker.

• Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

  3/18/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) today announced its financial and operating results for the three and twelve months ended December 31, 2020

• Cipher Pharmaceuticals Schedules Q4 2020 Earnings Release and Conference Call

  3/10/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q4 2020 financial results after the close on Thursday, March 18, 2021.

• Cipher Pharmaceuticals Enters into Co-Promotion Agreement with Verity Pharmaceuticals Inc.

  2/10/2021

   Cipher Pharmaceuticals Inc. (TSX: CPH)today announced it has entered into an exclusive co-promotion agreement with Verity Pharmaceuticals Inc. for the marketing, sales and co-promotion of Brinavess, Aggrastat and Trevyent.

• Cipher Pharmaceuticals Receives Arbitration Award on Trulance

  1/15/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health Ireland ("Bausch Health") relating to the License, Development and Commercialization Agreement (the "Agreement") of Trulance®